Baldwin Wealth Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Baldwin Wealth Partners’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$2.6K	–	1080
2024 Q3	$2.6K	Hold	500	–	–	﹤0.01%	927
2024 Q2	$1.28K	Hold	500	–	–	﹤0.01%	703
2024 Q1	$2.46K	Hold	500	–	–	﹤0.01%	637
2023 Q4	$4.39K	Hold	500	–	–	﹤0.01%	625
2023 Q3	$5.74K	Sell	500 -1,500	-75%	-$28.8K	﹤0.01%	615
2023 Q2	$50.6K	Buy	2,000 +1,500	+300%	+$46.7K	﹤0.01%	414
2023 Q1	$16.1K	Hold	500	–	–	﹤0.01%	570
2022 Q4	$9.23K	Hold	500	–	–	﹤0.01%	615
2022 Q3	$14K	Hold	500	–	–	﹤0.01%	488
2022 Q2	$7K	Hold	500	–	–	﹤0.01%	574
2022 Q1	$10K	Buy	+500	New	+$7.58K	﹤0.01%	544

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Baldwin Wealth Partners's RVNC Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 500 shares — an estimated $2.6K sold.

Baldwin Wealth Partners first reported a position in RVNC in Q1 2022 and held it in 11 quarters. The position peaked at $50.6K in Q2 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

Baldwin Wealth Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 500 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $2.6K.
Baldwin Wealth Partners first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 11 quarters.
Baldwin Wealth Partners's Revance Therapeutics, Inc. position peaked at $50.6K in Q2 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.